Dex-ketamine combined with dexmedetomidine on combined COPD pulmonary function preservation during one-lung ventilation in surgical patients of protect

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200062621

Enrollment

Unknown

Registered

2022-08-14

Start date

2022-10-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic obstructive pulmonary disease

Interventions

Group C:15min before induction of anesthesia, 10mL of normal saline was injected intravenously

Group A:15 minutes before induction of anesthesia, D-ketamine 0.25 mg/kg was diluted from normal saline to 10mL intravenously

Group D:15 minutes before induction of anesthesia, dexmedetomidine 0.8 ug/kg was diluted with normal saline to 20mL and pumped using a microinjection pump for 15 minutes

Group AD:15 minutes before induction of anesthesia, 0.25 mg/kg of dextro-ketamine was diluted from normal saline to 10mL intravenously combined with dexmedetomidine 0.8 ug/kg, diluted from normal sali

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. In line with the diagnostic criteria of COPD; 2. Patients were planned to undergo thoracoscopic radical resection of lung cancer under general anesthesia with double-lumen bronchial intubation, and the operation time was more than 2 hours; 3. ASA II-III grades.

Exclusion criteria

Exclusion criteria: 1. Patients with immune system, endocrine system, nervous and mental system diseases before surgery; 2. Patients with other respiratory diseases such as asthma and bronchiectasis; 3. Those with severe hypertension, diabetes, coronary heart disease, glaucoma and other diseases; 4. Patients with active infection such as nephritis or severe liver and kidney dysfunction; 5. Taking hormones one month before surgery and allergic or contraindicated users of the study drug dexketamine or dexmedetomidine.

Design outcomes

Primary

Measure	Time frame
peak pressure;plat pressure;PaCO2;PaO2;interleukin-6;interleukin-8;interleukin-10;tumor necrosis factor-a;malondialdehyde;superoxide dismutase;	—

Secondary

Measure	Time frame
airway resistance;Invasive arterial systolic pressure;Invasive arterial diastolic pressure;Invasive arterial mean pressure;Heart Rate;Postoperative Pain Prince.Henry Score;Postoperative nausea and vomiting;postoperative delirium;	—

Countries

China

Contacts

Public ContactZhiyuan Chen

The Second Affiliated Hospital of Fujian Medical University

chenzy0818@126.com+86 13506099319

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026